Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor and aldosterone antagonist for HFpEF (three-period crossover)
2020-000973-26Phase 2Completed
- Sponsor
- Faculdade de Medicina da Universidade do Porto
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in heart failure with preserved ejection fraction (HFpEF) comparing spironolactone monotherapy, dapagliflozin monotherapy and spironolactone + dapagliflozin combination (3 arms). Started Feb 2022; status: completed.
02
Drugs
dapagliflozinspironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2020-000973-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000973-26.